한빛사 논문
Abstract
Je-Min Choi1, Mi-Hyun Ahn2, Wook-Jin Chae1, Yung-Gook Jung1, Jae-Chul Park1, Hyun-Mi Song2, Young-Eun Kim2, Jung-Ah Shin2, Choon-Sik Park2, Jung-Won Park3, Tae-Kwann Park4, Jung-Hoon Lee5, Byung-Fhy Seo6, Kyun-Do Kim1, Eun-Sung Kim1, Dong-Ho Lee7, Seung-Kyou Lee7 & Sang-Kyou Lee1, 7
1 Department of Biotechnology, College of Engineering, Yonsei University, Seoul 120-749, Republic of Korea.
2 Genome Research Center for Allergy and Respiratory Disease, Soonchunhyang University Hospital, Bucheon, 420-767, Republic of Korea.
3 Department of Internal Medicine, Division of Allergy and Immunology, Yonsei Medical School, Seoul 120-749, Republic of Korea.
4 Department of Ophthalmology, Soonchunhyang University Hospital, Bucheon 420-767, Republic of Korea.
5 Department of Dermatology, Chungnam National University Hospital, Daesa-dong, Jung-gu, Daejon, 301-721, Republic of Korea.
6 Skin Research Institute, Amorepacific Co., R&D Center, Yongin 449-729, Republic of Korea.
7 ForHumanTech Co., Ltd, Kowoon Institute of Technology Innovation Bldg 706, Suwon, Republic of Korea.
CTLA-4 is a negative regulator of T-cell activation, and its inhibitory effects can be accomplished either by competition with CD28 or by transmitting negative signals through its intracellular domain. To utilize the cytoplasmic domain of CTLA-4 to suppress allergic inflammation, we fused it to a novel protein-transduction domain in the human transcriptional factor Hph-1. Transduction efficiency was verified in vitro and in vivo after ocular, intranasal and intradermal administration. After transduction into T cells, the Hph-1-ctCTLA-4 fusion protein inhibited the production of interleukin (IL)-2, and downregulated CD69 and CD25. Intranasal administration of Hph-1-ctCTLA-4 resulted in markedly reduced infiltration of inflammatory cells, secretion of T helper type 2 (TH2) cytokines, serum IgE levels and airway hyper-responsiveness in a mouse model of allergic airway inflammation. These results indicated that Hph-1-ctCTLA-4 constitutes an effective immunosuppressive protein drug for potential use in the treatment of allergic asthma, via nasal administration.
논문정보
TOP52006년 선정
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기